Our investigation revealed significant correlations between logMAR visual acuity at 1 year after the first injection and other factors (Table 2), as well as with age (R = 0.29; P = 0.02, linear regression analysis), number of anti-VEGF injections per year (R = 0.29; P = 0.02), presence or absence of hypertension (R = 0.27; P = 0.03), CRT before treatment (R = 0.32; P < 0.01), MBR at 1 month after the first injection (R = –0.44; P < 0.01), MBR at 1 year after the first injection (R = –0.66; P < 0.01), and TCR at 1 year after the first injection (R = 0.46; P < 0.01). The gene discussed is VEGFA; the disease is hypertensive disorder.